Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Clinical Characteristics and Outcome of Spontaneous Intracerebral Hemorrhage in Patients with End Stage Renal Disease on Hemodialysis
Cerebrovascular Disease and Interventional Neurology
P6 - Poster Session 6 (5:30 PM-6:30 PM)
6-007
Patients with ESRD on hemodialysis may have labile blood pressure (BP), with elevated BP prior to hemodialysis and hypotension post hemodialysis. The clinical characteristics and outcome of ICH in dialysis patients are not well defined.
To investigate the clinical features and outcome of spontaneous intracerebral hemorrhage (ICH) in patients with end stage renal disease (ESRD) on hemodialysis.

This is a single center cohort study. All ICH admissions at University of California, Irvine Medical Center from January 1, 2018 to July 31, 2022 were screened. Patients with ESRD on hemodialysis were selected for this study.

Among 449 ICH admissions during the study period, 27 patients (6.0%) were identified to have ESRD on hemodialysis. The average age of these patients was 51.5±19.1 and 63.0% of them were male. All patients had a history of hypertension and elevated systolic BP at initial presentation (202.8±35.9). 81.5% of patients had a history of diabetes mellitus while 51.9% had dyslipidemia. The most common ICH location was subcortical (40.7%). The average ICH score was 1.56±1.45. Their average ICU and hospital length of stay were 3±1.4 and 9.5±10.6, respectively. The mortality rate at hospital discharge was 22.2%. Multivariate regression analysis showed that mortality rate was independently associated with an ICH score greater than or equal to 3 (OR=34.1, 95% CI 1.45-802.58, p=0.03).

ICH in patients with ESRD on hemodialysis portends 22.2% mortality rate at hospital discharge. ICH score greater than or equal to 3 was found to be an independent predictor of poor outcome. In order to evaluate the clinical relevance of such findings, further studies comparing these to non-ESRD patients is warranted.

Authors/Disclosures
Kotaro Tsutsumi
PRESENTER
Mr. Tsutsumi has nothing to disclose.
Masaki Nagamine, MD (University of California, Irvine Medical Center) Dr. Nagamine has nothing to disclose.
Jonathan W. Chou, MD Dr. Chou has nothing to disclose.
Dana Stradling (University of California Irvine) Dana Stradling has nothing to disclose.
Diana Dench, RN (UCI Health) Mrs. Dench has nothing to disclose.
Wengui Yu, MD, PhD (UC Irvine, Neurology Dept) Dr. Yu has nothing to disclose.